FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfilePrescient Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
PTX.AX
Prescient Therapeutics Limited Stock AnalysisComprehensive stock analysis for Prescient Therapeutics Limited (PTX.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPTX.AX
PTX.AX
Prescient Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
PTX.AX
  1. Home
  2. Stocks
  3. Prescient Therapeutics Limited

Prescient Therapeutics Limited

🇦🇺PTX.AX•ASX

Prescient Therapeutics Limited

🇦🇺PTX.AX•ASX

Your view on PTX.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Prescient Therapeutics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
James McDonnell
Headquarters
Suite 2, Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
James McDonnell
Headquarters
Suite 2, Melbourne, VIC, AU
Description

Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types.

The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies.

Additionally, PTX-100, a RhoA inhibitor, is being developed to target both blood cancers and solid tumors, specifically those characterized by Ras and RhoA genetic mutations.

Prescient Therapeutics has also forged a strategic alliance with The University of Texas MD Anderson Cancer Center to advance the development of a blood cancer binder for their OmniCAR platform.

Founded in Melbourne, Australia, in 1986, the company operated as Virax Holdings Limited until its rebranding as Prescient Therapeutics Limited in December 2014.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Prescient Therapeutics Limited. Starting points for Prescient Therapeutics Limited: EPS -AUD 0.0067, beta 0.73 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Prescient Therapeutics Limited. Prescient Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Prescient Therapeutics Limited. Trailing twelve-month EPS for Prescient Therapeutics Limited stands at -AUD 0.0067. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis yearYear to Jun 2018Next yearYear to Jun 2024
Average estimateAUD 0.01−AUD 0.04
Lowest estimateAUD 0.01−AUD 0.04
Highest estimateAUD 0.01−AUD 0.04
Number of analysts11
A year ago——
Growth vs a year ago——

Revenue estimates

TotalThis yearYear to Jun 2018Next yearYear to Jun 2024
Average estimateAUD 12.91MAUD 2.00M
Lowest estimateAUD 12.91MAUD 2.00M
Highest estimateAUD 12.91MAUD 2.00M
Number of analysts11
A year ago——
Growth vs a year ago——

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Prescient Therapeutics Limited. Prescient Therapeutics Limited has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold PTX.AX19 companies
Compare PTX.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ADO.AXAnteoTech LimitedBasic MaterialsChemicals - Specialty—
AGN.AXArgenica Therapeutics LtdHealthcareBiotechnology—
ATX.AXAmplia Therapeutics LimitedHealthcareBiotechnology—
CYP.AXCynata Therapeutics LimitedHealthcareBiotechnology—
IIQ.AXINOVIQ LtdHealthcareMedical - Diagnostics & Research—
NOX.AXNoxopharm LimitedHealthcareBiotechnology—
NSB.AXNeuroScientific Biopharmaceuticals LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PALIPalisade Bio, Inc.HealthcareNASDAQ$168.9M
PANCPanacos Pharmaceuticals, Inc.HealthcareOTC$5,367
PAR.AXParadigm Biopharmaceuticals LimitedHealthcareASX—
PARDPoniard Pharmaceuticals, Inc.HealthcareOTC$150
PASGPassage Bio, Inc.HealthcareNASDAQ$12.9M
PBIGFParadigm Biopharmaceuticals LimitedHealthcareOTC$87.9M
PBLAPanbela Therapeutics, Inc.HealthcareOTC$53,889
PBLSParabilis Medicines, Inc.HealthcareNASDAQ$3.5B
PBMPsyence Biomedical Ltd.HealthcareNASDAQ$47,738
PBMWWPsyence Biomedical Ltd. WarrantHealthcareNASDAQ$869
PBYIPuma Biotechnology, Inc.HealthcareNASDAQ$373.3M
PCSAProcessa Pharmaceuticals, Inc.HealthcareNASDAQ$4.8M
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Prescient Therapeutics Limited.

PTX.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1